QQ客服 官方微博 反馈留言

	Nanotechnology-mediated immunochemotherapy combined with docetaxel and PD-L1 antibody increase therapeutic effects and decrease systemic toxicity
	Gu, Zili; Wang, Qingjie; Shi, Yanbin; Huang, Yi; Zhang, Jing; Zhang, Xinke; Lin, Guimei
刊名	JOURNAL OF CONTROLLED RELEASE
	2018
卷号	286页码:369-380
关键词	Nanotechnology Liposome Docetaxel PD-L1 Immunochemotherapy
DOI	10.1016/j.jconrel.2018.08.011
URL标识	查看原文
公开日期	[db:dc_date_available]
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4573061
专题	山东大学
作者单位	1.Shandong Univ, Sch Pharmaceut Sci, 44 West Wenhua Rd, Jinan 250012, Shandong, Peoples R China. 2.S
推荐引用方式 GB/T 7714	Gu, Zili,Wang, Qingjie,Shi, Yanbin,et al. Nanotechnology-mediated immunochemotherapy combined with docetaxel and PD-L1 antibody increase therapeutic effects and decrease systemic toxicity[J]. JOURNAL OF CONTROLLED RELEASE,2018,286:369-380.
APA	Gu, Zili.,Wang, Qingjie.,Shi, Yanbin.,Huang, Yi.,Zhang, Jing.,...&Lin, Guimei.(2018).Nanotechnology-mediated immunochemotherapy combined with docetaxel and PD-L1 antibody increase therapeutic effects and decrease systemic toxicity.JOURNAL OF CONTROLLED RELEASE,286,369-380.
MLA	Gu, Zili,et al."Nanotechnology-mediated immunochemotherapy combined with docetaxel and PD-L1 antibody increase therapeutic effects and decrease systemic toxicity".JOURNAL OF CONTROLLED RELEASE 286(2018):369-380.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。